Dark Forest Capital Management LP Altimmune, Inc. Transaction History

Dark Forest Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $132,383 - $222,410	16,105 New	16,105 $163,000
Q3 2023 Nov 13, 2023	BUY	$2.4 - $3.45 $65,304 - $93,874	27,210 Added 13.39%	230,353 $598,000
Q2 2023 Aug 14, 2023	BUY	$3.45 - $5.97 $549,267 - $950,471	159,208 Added 362.37%	203,143 $717,000
Q1 2023 May 12, 2023	BUY	$4.19 - $16.83 $184,087 - $739,426	43,935 New	43,935 $185,000
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $18,096 - $38,007	1,696 New	1,696 $22,000

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Dark Forest Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Dark Forest Capital Management LP with notifications on news.